Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer: Study protocol for a prospective, multicenter, open-label

BACKGROUND: Nazartinib is considered a new, permanent, and mutant-selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). It has a demonstrated efficacy to treat patients experiencing EGFR-mutated non-small cell cancer (NSCLC). The present study aims to explore the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Jun, Xiao, Zheng, Zhang, Lu-Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154402/
https://www.ncbi.nlm.nih.gov/pubmed/34032715
http://dx.doi.org/10.1097/MD.0000000000025992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154402/
https://www.ncbi.nlm.nih.gov/pubmed/34032715
http://dx.doi.org/10.1097/MD.0000000000025992

Ejemplares similares